Lasofoxifene

Lasofoxifene

Clinical data
Trade names	Fablyn
Routes of administration	By mouth
Drug class	Selective estrogen receptor modulator
ATC code	G03XC03 (WHO)
Identifiers
IUPAC name (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
CAS Number	180916-16-9 N
PubChem CID	216416
IUPHAR/BPS	7542
ChemSpider	187585 Y
UNII	337G83N988
ChEBI	CHEBI:135938
ChEMBL	ChEMBL328190 Y
CompTox Dashboard (EPA)	DTXSID50171037
Chemical and physical data
Formula	C28H31NO2
Molar mass	413.55 g/mol 563.64 g/mol (tartrate) g·mol−1
3D model (JSmol)	Interactive image
SMILES O(c1ccc(cc1)[C@@H]4c2ccc(O)cc2CC[C@@H]4c3ccccc3)CCN5CCCC5
InChI InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1 Y Key:GXESHMAMLJKROZ-IAPPQJPRSA-N Y
NY (what is this?)  (verify)

Lasofoxifene, sold under the brand name Fablyn, is a nonsteroidal selective estrogen receptor modulator (SERM) which is marketed by Pfizer in Lithuania and Portugal for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy,^[1][2] and the result of an exclusive research collaboration with Ligand Pharmaceuticals (LGND). It also appears to have had a statistically significant effect of reducing breast cancer in women according to a study published in The Journal of the National Cancer Institute.